Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, 3rd edition
CHI Insight Pharma Reports
October 1, 2010 261 Pages - SKU: CHI6671624
|
|
The Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the distribution partnering agreements entered into by the worlds leading biopharma companies.
The report provides a detailed understand and analysis of how and why companies enter distribution deals.
The majority of deals are multicomponent whereby the licensor offers a right to distribute the resultant product of the research collaboration. There are also numerous pure distribution deals whereby the products originator takes on a distribution partner in order to maximize a products presence in the marketplace.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
|
- Executive Summary
- Chapter 1 - Introduction
- Chapter 2 - Trends in distribution dealmaking
- 2.1. Introduction
- 2.2. Definiton of distribution dealmaking
- 2.3. Trends in distribution deals since 2000
- 2.4. Pure deals and multi-component deals
- 2.5.1. Attributes of pure distribution deals
- 2.5.2. Attributes of distribution in multi-component deals
- 2.6. Aligning partners to make the distribution agreement work
- 2.7. The emergence of direct to pharmacy distribution in Europe
- 2.7.1. The role of consolidated distribution
- Chapter 3 - Overview of distribution deal structure
- 3.1. Introduction
- 3.2. Pure versus multi-component distribution deals
- 3.3. Pure distribution agreement structure
- 3.3.1. Example distribution agreements
- 3.3.1.a. Case study 1: BioSite - Fisher Scientific - January 2006
- 3.3.1.b. Case study 2: Inverness Medical Innovations - Matritech - November 2006
- 3.4. Distribution rights as part of a wider alliance agreement
- 3.4.1. Example distribution clauses
- 3.4.1.a. Case study 3: Ipsen - Aesthetica - March 2006
- 3.4.1.b. Case study 4: Gilead - Bristol-Myers Squibb - September 2006
- Chapter 4 - Leading distribution deals
- 4.1. Introduction
- 4.2. Top distribution deals by value
- 4.3. Top pure distribution deals
- 4.4. Top distribution deals signed by bigpharma
- 4.5. Most active distribution dealmakers
- 4.6. Bigpharma distribution deal activity
- Chapter 5 - Bigpharma distribution agreements
- 5.1. Introduction
- 5.2. How to use distribution agreements
- 5.3. Company distribution agreement listings
- Abbott
- Actavis
- Alcon Labs
- Allergan
- Amgen
- Astellas
- AstraZeneca
- Baxter
- Bayer
- Biogen Idec
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Cephalon
- Chugai
- CSL
- Daiichi Sankyo
- Dainnipon Sumitomo
- Eisai
- Eli Lilly
- Forest Laboratories
- Genentech
- Genzyme
- Gilead Sciences
- GlaxoSmithKline
- Hospira
- Johnson & Johnson
- Lundbeck
- Menarini
- Merck & Co
- Merck Serono
- Mitsubishi-Tanabe
- Mylan
- Novartis
- Novo Nordisk
- Nycomed Pharma
- Otsuka
- Pfizer
- Procter & Gamble
- Ratiopharm
- Roche
- Sanofi-Aventis
- Schering Plough
- Servier
- Shire
- Solvay
- Takeda
- Teva
- UCB
- Watson
- Wyeth
- Chapter 6 - Distribution agreement directory 2003-2010
- 6.1. Introduction
- 6.2. Company A-Z
- 6.3. By therapy area
- Accident/Hospital/Trauma
- Blood/Lymphatic System
- Cardiovascular
- Central nervous System
- Dermatology
- Gastrointestinal
- Genitourinary
- Genetic
- Autoimmune/Inflammatory
- Infection
- Metabolism
- Musculoskeletal
- Oncology
- Respiratory
- Sensory Organ / Oral Health
- 6.4. By stage of development at signing
- Discovery
- Preclinical
- Phase I
- Phase II
- Phase III
- Registration
- Market
- Appendices
- Appendix 1 - Distribution references
- Appendix 2 - Resources
- Appendix 3 - Deal type definitions
- Appendix 4 - Example distribution contract document
- About CurrentPartnering
- Recent report titles from CurrentPartnering Order Form - Reports Order form - Company Dealmaking Profiles Order Form - Report Update Subscription Order Form - CD-Rom
- Figures in report
- Figure 1: Definition of distribution dealmaking
- Figure 2: Trends in distribution deal announcements, 2000-2009
- Figure 3: Distribution deals signed at what phase of development, 2000-2009
- Figure 4: Pure versus multi-component distribution deal announcements, 2000-2009
- Figure 5: Stage of development at which pure and multi-component distribution deals are announced 2000-2009
- Figure 6: Issues in implementing distribution agreements
- Figure 7: Recent consolidated distribution deals
- Figure 8: Components of the distribution deal structure
- Figure 9: Top 50 distribution deals by value since 2003
- Figure 10: Top pure distribution deals by value since 2003
- Figure 11: Top distribution deals signed by bigpharma value since 2003
- Figure 12: Most active distribution dealmakers 2003-2009
- Figure 13: Characteristics of active distribution dealmakers
- Figure 14: Bigpharma - top 50 - distribution deals since 2003
- Figure 15: Online partnering resources
- Figure 16: Deal type definitions
- Figure 17: Distribution agreement between Draxis Health and GE Healthcare
Share this report
Other tasks Related Markets Pharmaceuticals Company Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
